BIVI
BioVie Inc. NASDAQ Listed Sep 18, 2020$1.94
Pre-mkt
$1.94
+0.00%
Mkt Cap $2.9M
52w Low $1.06
9.1% of range
52w High $10.70
50d MA $1.56
200d MA $1.51
P/E (TTM)
—
EV/EBITDA
—
P/B
0.1x
Debt/Equity
0.0x
ROE
-85.6%
P/FCF
-0.2x
RSI (14)
65.40
ATR (14)
$0.16
Beta
0.56
50d MA
$1.56
200d MA
$1.51
Avg Volume
134.2K
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.
680 West Nye Lane · Carson City, NV 89703 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 6, 2026 | AMC | -0.81 | -0.77 | +4.9% | 1.13 | -3.5% | +2.7% | +2.6% | -3.4% | -3.5% | +14.4% | — |
| Nov 10, 2025 | AMC | -0.79 | -0.98 | -24.1% | 1.56 | -1.3% | -3.2% | +6.6% | -7.5% | +0.7% | -6.0% | — |
| Aug 15, 2025 | AMC | -4.40 | -0.24 | +94.6% | 1.65 | +1.8% | +6.1% | -9.1% | -1.9% | -2.6% | +5.3% | — |
| May 12, 2025 | AMC | -3.20 | -1.50 | +53.1% | 11.50 | -1.7% | -7.0% | +2.8% | -4.5% | -1.9% | +3.9% | — |
| Feb 11, 2025 | AMC | -16.00 | -4.60 | +71.2% | 18.00 | -9.4% | -3.9% | +2.3% | +3.4% | -2.7% | -3.9% | — |
| Nov 13, 2024 | AMC | -16.00 | -7.00 | +56.2% | 34.10 | -0.3% | -6.7% | +0.3% | +6.9% | +2.9% | -4.3% | — |
| Sep 30, 2024 | AMC | -15.00 | -66.00 | -340.0% | 12.00 | +1.7% | -4.2% | +3.5% | -0.8% | +0.8% | +0.8% | — |
| May 14, 2024 | AMC | -0.33 | -20.00 | -5960.6% | 49.90 | +0.7% | -0.8% | +0.8% | -1.4% | -4.2% | +2.7% | — |
| Feb 12, 2024 | AMC | -32.00 | -22.00 | +31.2% | 114.00 | +0.0% | -3.5% | +5.5% | +1.7% | +4.2% | -8.9% | — |
| Nov 8, 2023 | AMC | -0.31 | -29.00 | -9254.8% | 426.00 | -6.1% | -29.3% | +9.0% | -4.6% | -0.6% | +1.3% | — |
| Aug 16, 2023 | AMC | -37.00 | -23.00 | +37.8% | 378.00 | -0.5% | -5.6% | +2.0% | -3.0% | +0.8% | +0.8% | — |
| May 12, 2023 | AMC | -0.35 | -43.00 | -9999.0% | 739.00 | +1.5% | +0.9% | -6.3% | +2.7% | -1.5% | -0.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 30 | Oppenheimer | Maintains | Outperform → Outperform | — | $196.00 | $190.00 | -3.1% | -8.2% | -6.7% | +3.6% | +2.3% | -0.6% |
| Aug 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $353.00 | $350.00 | -0.8% | +0.8% | +0.8% | -3.6% | -2.6% | +1.5% |
| Jul 18 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $506.00 | $525.00 | +3.8% | +1.8% | +0.0% | -1.9% | -0.1% | -1.3% |
| May 17 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $699.00 | $721.00 | +3.1% | +2.7% | -1.5% | -0.8% | -4.0% | +1.6% |
| May 17 | Oppenheimer | Maintains | Outperform → Outperform | — | $699.00 | $721.00 | +3.1% | +2.7% | -1.5% | -0.8% | -4.0% | +1.6% |
| Feb 14 | Oppenheimer | Maintains | Outperform → Outperform | — | $506.00 | $515.00 | +1.8% | +5.1% | +4.7% | -1.1% | +4.9% | -2.4% |
| Sep 28 | EF Hutton | Maintains | Buy → Buy | — | $236.00 | $241.00 | +2.1% | +8.5% | -5.9% | +3.3% | -2.4% | +8.2% |
| Jul 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $210.00 | $227.00 | +8.1% | +5.2% | +11.3% | -4.1% | -8.1% | +0.9% |
| Mar 17 | EF Hutton | Maintains | Buy → Buy | — | $303.00 | $328.00 | +8.3% | +9.6% | +20.2% | +0.8% | +0.7% | -4.6% |
| Mar 15 | Oppenheimer | Maintains | Outperform → Outperform | — | $277.00 | $300.00 | +8.3% | +1.4% | +7.8% | +9.6% | +20.2% | +0.8% |
| Nov 30 | B. Riley Securities | Maintains | Buy → Buy | — | $660.00 | $658.00 | -0.3% | -2.4% | -8.2% | -2.2% | -7.6% | -2.2% |
| Jan 15 | B. Riley FBR | Maintains | Buy → Buy | — | $2994.00 | $3210.00 | +7.2% | +26.7% | +11.0% | -10.0% | -6.8% | -1.2% |
No insider trades available.
No recent filings available.
Institutional (13F) — Top 18
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 120,444 | $140K | Added | Dec 2025 |
| 2 | Prelude Capital Management, Llc | 92,063 | $129K | — | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 84,067 | $118K | New | Mar 2026 |
| 4 | Renaissance Technologies Llc | 67,918 | $95K | Added | Mar 2026 |
| 5 | Citadel Advisors Llc | 45,292 | $63K | Added | Mar 2026 |
| 6 | Hrt Financial Lp | 23,482 | $32K | New | Mar 2026 |
| 7 | Northern Trust Corp | 14,189 | $20K | — | Mar 2026 |
| 8 | Jane Street Group, Llc | 10,475 | $12K | New | Dec 2025 |
| 9 | Pnc Financial Services Group, Inc. | 1,000 | $1K | — | Mar 2026 |
| 10 | Wells Fargo & Company/mn | 27 | $38 | New | Mar 2026 |
| 11 | Ubs Group Ag | 6 | $8 | Reduced | Mar 2026 |
| 12 | Jpmorgan Chase & Co | 5 | $7 | — | Mar 2026 |
| 13 | Gill Capital Partners, Llc | 2 | $3 | New | Mar 2026 |
| 14 | Bnp Paribas Financial Markets | 2 | $3 | — | Mar 2026 |
| 15 | Albion Financial Group /ut | 1 | $2 | — | Mar 2026 |
| 16 | Danske Bank A/s | 1 | $1 | — | Mar 2026 |
| 17 | Fmr Llc | — | — | Reduced | Mar 2026 |
| 18 | Royal Bank Of Canada | 205 | — | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 4
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 46,917 | $65K | Feb 2026 |
| 2 | Fidelity Series Total Market Index Fund | 6,950 | $10K | Feb 2026 |
| 3 | Fidelity Total Market Index Fund | 2,401 | $3K | Feb 2026 |
| 4 | Fidelity Nasdaq Composite Index Fund | 230 | $317 | Feb 2026 |
Valuation
Market Cap
$2.9M
Enterprise Value
-$14.7M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.01x
P/B
0.15x
P/S
—
P/FCF
-0.15x
EV/EBITDA
—
Shares Out
1.5M
Financials (TTM)
Revenue
$0
Net Income
-$19.9M
EBITDA
-$19.7M
Free Cash Flow
-$19.0M
Op Cash Flow
-$19.0M
EPS Basic
$-12.12
EPS Diluted
$-4.27
EPS Forward
$-2.95
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$21.6M
Total Liab.
$2.6M
Total Equity
$19.0M
Cash
$17.5M
LT Debt
$0
Book Value/Sh
$12.87
Debt/Equity
0.02x
Current Ratio
9.10
Quick Ratio
9.10
Returns & Growth
ROE
-85.6%
ROA
-73.3%
ROIC
-93.3%
Rev Growth YoY
+0.0%
EPS Growth YoY
+83.4%
Price Returns
2W
+2.9%
1M
-13.9%
3M
+2.9%
6M
-5.3%
12M
-86.3%
Technicals
52W High
$10.70
52W Low
$1.06
50d MA
$1.56
200d MA
$1.51
RSI (14)
65.40
ATR (14)
$0.16
Beta
0.56
Avg Volume
134K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 24, 2026 9:44pm
· Source: financialmodelingprep.com